Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Receivables - Other data on file, last reported at $1.0 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.0 million, down 58.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 58.33% YoY), and the FY2025 annual result was $1.0 million, down 50.0% from the prior year.
• Receivables - Other held at $1.0 million in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $12.7 million in Q1 2023 and troughed at $200000.0 in Q1 2024.
• A 5-year average of $2.7 million and a median of $2.1 million in 2025 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other sank 98.43% in 2024, then surged 1100.0% in 2025.
• A 5-year view of Receivables - Other shows it stood at $6.4 million in 2022, then slumped by 82.81% to $1.1 million in 2023, then soared by 81.82% to $2.0 million in 2024, then sank by 50.0% to $1.0 million in 2025, then changed by 0.0% to $1.0 million in 2026.
• Business Quant data shows RARE's Receivables - Other at $1.0 million in Q1 2026, $1.0 million in Q4 2025, and $2.1 million in Q3 2025.